176,750 Abbott Laboratories $ABT Shares Bought by Norris Perne & French LLP MI

Norris Perne & French LLP MI increased its stake in Abbott Laboratories (NYSE:ABT) by 112.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 334,455 shares of the healthcare product maker’s stock after purchasing an additional 176,750 shares during the quarter. Abbott Laboratories makes up approximately 1.5% of Norris Perne & French LLP MI’s investment portfolio, making the stock its 19th largest position. Norris Perne & French LLP MI’s holdings in Abbott Laboratories were worth $33,054,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. Signaturefd LLC raised its position in Abbott Laboratories by 11.9% during the third quarter. Signaturefd LLC now owns 45,051 shares of the healthcare product maker’s stock worth $4,452,000 after acquiring an additional 4,776 shares in the last quarter. BG Investment Services LLC acquired a new stake in Abbott Laboratories in the third quarter valued at $269,000. Citizens Financial Group Inc. RI lifted its stake in Abbott Laboratories by 4.4% in the third quarter. Citizens Financial Group Inc. RI now owns 135,452 shares of the healthcare product maker’s stock valued at $13,387,000 after acquiring an additional 5,750 shares during the last quarter. Simplicity Wealth LLC grew its position in shares of Abbott Laboratories by 5.5% in the 3rd quarter. Simplicity Wealth LLC now owns 28,385 shares of the healthcare product maker’s stock valued at $2,805,000 after acquiring an additional 1,477 shares during the period. Finally, Madrona Financial Services LLC bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $212,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Price Performance

NYSE:ABT opened at $103.70 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company has a market cap of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.92 and a beta of 0.59. The firm’s fifty day moving average price is $105.15 and its two-hundred day moving average price is $98.32. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting the consensus estimate of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The company’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.30 earnings per share. Equities analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is 94.03%.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent analyst reports. Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday. Piper Sandler reiterated an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Royal Bank Of Canada lowered their price target on Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Wall Street Zen upgraded Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.